Contributors: Anker, M. S.; Hadzibegovic, S.; Lena, A.; Belenkov, Y.; Bergler-Klein, J.; de Boer, R. A.; Farmakis, D.; von Haehling, S.; Iakobishvili, Z.; Maack, C.; Pudil, R.; Skouri, H.; Cohen-Solal, A.; Tocchetti, C.; Coats, A. J. S.; Seferovic, P. M.; Lyon, A. R.
نبذة مختصرة : While anti-cancer therapies, including chemotherapy, immunotherapy, radiotherapy, and targeted therapy, are constantly advancing, cardiovascular toxicity has become a major challenge for cardiologists and oncologists. This has led to an increasing demand of cardio-oncology units in Europe and a growing interest of clinicians and researchers. The Heart Failure 2019 meeting of the Heart Failure Association of the European Society of Cardiology in Athens has therefore created a scientific programme that included four dedicated sessions on the topic along with several additional lectures. The major points that were discussed at the congress included the implementation and delivery of a cardio-oncology service, the collaboration among cardio-oncology experts, and the risk stratification, prevention, and early recognition of cardiotoxicity. Furthermore, sessions addressed the numerous different anti-cancer therapies associated with cardiotoxic effects and provided guidance on how to treat cancer patients who develop cardiovascular disease before, during, and after treatment.
Processing Request
No Comments.